August 30, 2021 -- Laronde has secured $440 million in series B funding that it plans to use to further develop its Endless RNA platform.
The round was led by Laronde's founding company, Flagship Pioneering. Endless RNA is an "engineered form of RNA that can be programmed to express therapeutic proteins inside the body," according to the firm. Endless RNA is redosable, and it can be administered through simple delivery mechanisms, resulting in highly tunable protein levels. This allows for controlled expression of secreted peptides, proteins, antibodies, and vaccine constructs through an array of delivery options.
Additional investors include T. Rowe Price Associates, Invus, the Canada Pension Plan Investment Board, and Fidelity Management and Research, according to Laronde.